Travere Therapeutics: Q2 Earnings Insights

Shares of Travere Therapeutics TVTX were flat in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 77.27% over the past year to ($0.39), which beat the estimate of ($0.68).

Revenue of $54,617,000 up by 12.78% from the same period last year, which beat the estimate of $50,330,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Travere Therapeutics hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Jul 29, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/byztc8jo

Price Action

52-week high: $33.09

Company's 52-week low was at $12.75

Price action over last quarter: down 30.83%

Company Profile

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease.